New 5-HT2c receptor agonists

被引:28
作者
Bishop, MJ
Nilsson, BM
机构
[1] GlaxoSmithKline, Res&Dev, Res Triangle Pk, NC 27709 USA
[2] Biovitrium AB, SE-11276 Stockholm, Sweden
关键词
5-hydroxytryptamme (5-HT); 5-HTx agonist; 5-HT2C receptor; Alzheimer's disease; anxiety; depression; epilepsy; G-protein-coupled receptor; hot flushes; obesity; obsessive-compulsive disorder (OCD); serotomn; sexual dysfunction; urinary incontinence;
D O I
10.1517/13543776.13.11.1691
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
While there is evidence for the involvement of different serotonin (5-hydroxytryptamine; 5-HT) receptors in the regulation of food intake and body weight maintenance, the data supporting the role of the 5-HT2C receptor are especially strong. This information has elevated 5-HT2C receptor activation into one of the most competitive research areas for antiobesity therapy, a therapeutic area with few (if any) safe, effective pharmacological agents available. Varying amounts of evidence also exist to support the use of 5-HT2C agonists for the pharmacological treatment of several other conditions, including anxiety, depression, obsessive-compulsive disorder, sexual dysfunction, epilepsy, urinary incontinence and hot flushes. The therapeutic potential of 5-HT2C receptor modulation has spawned a successful search for 5-HT2C receptor agonists. This review will focus on recent patent applications through August 2003 that describe compounds that have agonist activity at the 5-HT2C receptor, and should be complementary to previous Expert Opinion discussions on the 5-HT2C receptor [1-7].
引用
收藏
页码:1691 / 1705
页数:15
相关论文
共 161 条
[81]  
HOFFMANNLAROCHE F, 2003, Patent No. 03064423
[82]  
HOYER D, 1994, PHARMACOL REV, V46, P157
[83]   The 5-HT2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs [J].
Isaac, M .
DRUGS OF THE FUTURE, 2001, 26 (04) :383-393
[84]   Pyrrolo[3,2,1-ij]quinoline derivatives, a 5-HT2c receptor agonist with selectivity over the 5-HT2a receptor:: Potential therapeutic applications for epilepsy and obesity [J].
Isaac, M ;
Slassi, A ;
O'Brien, A ;
Edwards, L ;
MacLean, N ;
Bueschkens, D ;
Lee, DKH ;
McCallum, K ;
De Lannoy, I ;
Demchyshyn, L ;
Kamboj, R .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (09) :919-921
[85]  
Jackson M., 1972, U.S. Patent, Patent No. [US3652588 A, 3652588]
[86]  
Jenck F, 1998, Expert Opin Investig Drugs, V7, P1587, DOI 10.1517/13543784.7.10.1587
[87]   Effects of RO 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety [J].
Kennett, G ;
Lightowler, S ;
Trail, B ;
Bright, F ;
Bromidge, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (02) :197-204
[88]   SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist [J].
Kennett, GA ;
Wood, MD ;
Bright, F ;
Trail, B ;
Riley, G ;
Holland, V ;
Avenell, KY ;
Stean, T ;
Upton, N ;
Bromidge, S ;
Forbes, IT ;
Brown, AM ;
Middlemiss, DN ;
Blackburn, TP .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :609-620
[89]  
KENNETT GA, 1993, CURR OPIN INVEST DR, V2, P317
[90]   AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats [J].
Kihara, H ;
Hirose, K ;
Koganei, H ;
Sasaki, N ;
Yamamoto, H ;
Kimura, A ;
Nishimori, T ;
Shoji, M ;
Yoshimoto, R .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :523-530